NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Monday that its fourth-quarter revenues climbed 24 percent, topping analysts' consensus estimate.

The San Diego-based genetic analysis products firm brought in total revenues of $309.3 million for the three months ended Dec. 30, 2012, in line with its pre-announcement and up from $250.1 million for the fourth quarter of 2011. It beat the consensus Wall Street estimate of $305.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."